News Related to Malignancies

Eledon Pharmaceuticals Presents Long-Term Phase 2 BESTOW Data Showing Tegoprubart Benefits Over Tacrolimus in Kidney Transplant

Jun 22, 2026

Eledon Pharmaceuticals reported positive long-term Phase 2 BESTOW trial results for tegoprubart in kidney transplant, showing sustained kidney function benefits and improved patient outcomes versus tacrolimus. The company outlined plans for a Phase 3 registrational trial and seeks an FDA meeting in early 2027. Safety data indicated lower adverse event rates with tegoprubart.

Priovant's Brepocitinib Shows Positive Phase 3 Results in Dermatomyositis Trial

Mar 29, 2026

Priovant Therapeutics' brepocitinib demonstrated significant efficacy in the Phase 3 VALOR trial for dermatomyositis, meeting its primary endpoint with a 15.3-point greater improvement in Total Improvement Score versus placebo at Week 52. The treatment showed meaningful corticosteroid tapering and improvements across all nine key secondary endpoints, with benefits sustained through one year. Additional analyses revealed rapid itch reduction and improved skin-related quality of life in patients.

Regulatory T Cell Therapies Advance for Autoimmune Diseases and Transplant Rejection

Feb 13, 2026

Engineered regulatory T cell therapies are progressing through clinical trials for autoimmune diseases and organ transplant rejection, with CAR-Treg candidates showing promising early results in rheumatoid arthritis and other conditions.

TROP2-Targeted ADCs with Topoisomerase I Inhibitors Advance in Oncology

Nov 04, 2025

Antibody-drug conjugates targeting TROP2 with topoisomerase I inhibitor payloads are currently marketed in breast and lung cancer, with over 100 such ADCs now in clinical trials for various malignancies including gastrointestinal tumors.